Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Jun 29. pii: S0360-3016(18)31014-9. doi: 10.1016/j.ijrobp.2018.06.023. [Epub ahead of print]

PMID:
29966725
2.

Heterogeneity in metastatic breast cancer 18F-fluoroestradiol uptake - clinically actionable, biologically illuminating?

Kurland BF, Oesterreich S.

J Nucl Med. 2018 Jun 14. pii: jnumed.118.214304. doi: 10.2967/jnumed.118.214304. [Epub ahead of print] No abstract available.

PMID:
29903931
3.

Nondaily Smokers' Changes in Cigarette Consumption With Very Low-Nicotine-Content Cigarettes: A Randomized Double-blind Clinical Trial.

Shiffman S, Kurland BF, Scholl SM, Mao JM.

JAMA Psychiatry. 2018 Jun 14. doi: 10.1001/jamapsychiatry.2018.1831. [Epub ahead of print]

PMID:
29902305
4.

FDG PET and FES PET Predict PFS on Endocrine Therapy-Response.

Kurland BF, Peterson LM, Linden HM, Mankoff DA.

Clin Cancer Res. 2018 Jan 1;24(1):249-250. doi: 10.1158/1078-0432.CCR-17-2980. No abstract available.

PMID:
29298808
5.

Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.

Volonte D, Vyas AR, Chen C, Dacic S, Stabile LP, Kurland BF, Abberbock SR, Burns TF, Herman JG, Di YP, Galbiati F.

J Biol Chem. 2018 Feb 2;293(5):1794-1809. doi: 10.1074/jbc.M117.815902. Epub 2017 Dec 15.

PMID:
29247004
6.

Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.

Stabile LP, Farooqui M, Kanterewicz B, Abberbock S, Kurland BF, Diergaarde B, Siegfried JM.

J Thorac Oncol. 2018 Mar;13(3):399-412. doi: 10.1016/j.jtho.2017.11.126. Epub 2017 Dec 9.

PMID:
29233790
7.

Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.

Chang AE, Wu QV, Jenkins IC, Specht JM, Gadi VK, Gralow JR, Salazar LG, Kurland BF, Linden HM.

Clin Breast Cancer. 2018 Feb;18(1):e143-e149. doi: 10.1016/j.clbc.2017.10.005. Epub 2017 Oct 9.

PMID:
29174203
8.

FDG PET and FES PET Predict PFS on Endocrine Therapy-Response.

Kurland BF, Linden HM, Mankoff DA.

Clin Cancer Res. 2017 Jul 1;23(13):3475. doi: 10.1158/1078-0432.CCR-17-0479. No abstract available.

9.

DCE-MRI Background Parenchymal Enhancement Quantified from an Early versus Delayed Post-contrast Sequence: Association with Breast Cancer Presence.

Wu S, Zuley ML, Berg WA, Kurland BF, Jankowitz RC, Sumkin JH, Gur D.

Sci Rep. 2017 May 18;7(1):2115. doi: 10.1038/s41598-017-02341-8.

10.

Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.

Chatterjee S, Huang EH, Christie I, Kurland BF, Burns TF.

Mol Cancer Ther. 2017 May;16(5):793-804. doi: 10.1158/1535-7163.MCT-16-0677. Epub 2017 Feb 6.

11.

Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey.

Kurland BF, Aggarwal S, Yankeelov TE, Gerstner ER, Mountz JM, Linden HM, Jones EF, Bodeker KL, Buatti JM.

Tomography. 2016 Dec;2(4):276-282. doi: 10.18383/j.tom.2016.00169.

12.

For Health-Related Quality of Life and Other Longitudinal Data, Analysis Should Distinguish Between Truncation by Death and Data Missing Because of Nonresponse.

Kurland BF, Egleston BL.

J Clin Oncol. 2016 Dec 20;34(36):4449. doi: 10.1200/JCO.2016.69.1220. Epub 2016 Oct 31. No abstract available.

PMID:
27601541
13.

Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer.

Wu S, Berg WA, Zuley ML, Kurland BF, Jankowitz RC, Nishikawa R, Gur D, Sumkin JH.

Breast Cancer Res. 2016 Jul 22;18(1):76. doi: 10.1186/s13058-016-0734-0.

14.

Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.

Metz HE, Kargl J, Busch SE, Kim KH, Kurland BF, Abberbock SR, Randolph-Habecker J, Knoblaugh SE, Kolls JK, White MF, Houghton AM.

Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8795-800. doi: 10.1073/pnas.1601989113. Epub 2016 Jul 20.

15.

Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.

Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM.

Clin Cancer Res. 2017 Jan 15;23(2):407-415. doi: 10.1158/1078-0432.CCR-16-0362. Epub 2016 Jun 24.

16.

ATM protein is deficient in over 40% of lung adenocarcinomas.

Villaruz LC, Jones H, Dacic S, Abberbock S, Kurland BF, Stabile LP, Siegfried JM, Conrads TP, Smith NR, O'Connor MJ, Pierce AJ, Bakkenist CJ.

Oncotarget. 2016 Sep 6;7(36):57714-57725. doi: 10.18632/oncotarget.9757.

17.

Diffusion-Weighted Breast Magnetic Resonance Imaging: A Semiautomated Voxel Selection Technique Improves Interreader Reproducibility of Apparent Diffusion Coefficient Measurements.

Rahbar H, Kurland BF, Olson ML, Kitsch AE, Scheel JR, Chai X, Usoro J, Lehman CD, Partridge SC.

J Comput Assist Tomogr. 2016 May-Jun;40(3):428-35. doi: 10.1097/RCT.0000000000000372.

18.

Effect of 18F-FDG uptake time on lesion detectability in PET imaging of early stage breast cancer.

Wangerin KA, Muzi M, Peterson LM, Linden HM, Novakova A, O'Sullivan F, Kurland BF, Mankoff DA, Kinahan PE.

Tomography. 2015 Sep;1(1):53-60.

19.

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM.

Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22.

20.

Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.

Nedrow JR, Latoche JD, Day KE, Modi J, Ganguly T, Zeng D, Kurland BF, Berkman CE, Anderson CJ.

Mol Imaging Biol. 2016 Jun;18(3):402-10. doi: 10.1007/s11307-015-0908-7.

PMID:
26552656
21.

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.

Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss KR, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla SL, Lee AV, Oesterreich S.

Clin Cancer Res. 2016 Mar 1;22(5):1130-7. doi: 10.1158/1078-0432.CCR-15-1534. Epub 2015 Oct 23.

22.

Tumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles.

Partridge SC, Kurland BF, Liu CL, Ho RJ, Ruddell A.

Sci Rep. 2015 Oct 26;5:15641. doi: 10.1038/srep15641.

23.

Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.

Kurland BF, Muzi M, Peterson LM, Doot RK, Wangerin KA, Mankoff DA, Linden HM, Kinahan PE.

J Nucl Med. 2016 Feb;57(2):226-30. doi: 10.2967/jnumed.115.162289. Epub 2015 Oct 22.

24.

Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions.

Weissfeld JL, Lin Y, Lin HM, Kurland BF, Wilson DO, Fuhrman CR, Pennathur A, Romkes M, Nukui T, Yuan JM, Siegfried JM, Diergaarde B.

J Thorac Oncol. 2015 Nov;10(11):1538-45. doi: 10.1097/JTO.0000000000000666.

25.

Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma.

Ceschin R, Kurland BF, Abberbock SR, Ellingson BM, Okada H, Jakacki RI, Pollack IF, Panigrahy A.

AJNR Am J Neuroradiol. 2015 Nov;36(11):2170-6. doi: 10.3174/ajnr.A4428. Epub 2015 Sep 3.

26.

External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.

Cho E, Mostaghel EA, Russell KJ, Liao JJ, Konodi MA, Kurland BF, Marck BT, Matsumoto AM, Dalkin BL, Montgomery RB.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):236-43. doi: 10.1016/j.ijrobp.2015.01.020. Epub 2015 Mar 12.

27.

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG.

Cancer. 2015 Feb 1;121(3):448-56. doi: 10.1002/cncr.29042. Epub 2014 Oct 1.

28.

Quantitative imaging biomarkers: a review of statistical methods for technical performance assessment.

Raunig DL, McShane LM, Pennello G, Gatsonis C, Carson PL, Voyvodic JT, Wahl RL, Kurland BF, Schwarz AJ, Gönen M, Zahlmann G, Kondratovich MV, O'Donnell K, Petrick N, Cole PE, Garra B, Sullivan DC; QIBA Technical Performance Working Group.

Stat Methods Med Res. 2015 Feb;24(1):27-67. doi: 10.1177/0962280214537344. Epub 2014 Jun 11. Review.

29.

Assessment of joint and fascia manifestations in chronic graft-versus-host disease.

Inamoto Y, Pidala J, Chai X, Kurland BF, Weisdorf D, Flowers ME, Palmer J, Arai S, Jacobsohn D, Cutler C, Jagasia M, Goldberg JD, Martin PJ, Pavletic SZ, Vogelsang GB, Lee SJ, Carpenter PA; Chronic GVHD Consortium.

Arthritis Rheumatol. 2014 Apr;66(4):1044-52. doi: 10.1002/art.38293.

30.

Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, Cutler C, Weisdorf D, Kurland BF, Carpenter PA, Pidala J, Pavletic SZ, Wood W, Jacobsohn D, Arai S, Arora M, Jagasia M, Vogelsang GB, Lee SJ.

Biol Blood Marrow Transplant. 2014 Mar;20(3):337-44. doi: 10.1016/j.bbmt.2013.11.025. Epub 2013 Dec 4.

31.

A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM.

Mol Imaging Biol. 2014 Jun;16(3):431-40. doi: 10.1007/s11307-013-0699-7. Epub 2013 Oct 30.

32.
33.

A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.

Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R, Nelson PS, Fang M.

PLoS One. 2013 Sep 30;8(9):e74671. doi: 10.1371/journal.pone.0074671. eCollection 2013.

34.

ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.

Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath S, Martins RG.

Br J Cancer. 2013 Oct 15;109(8):2096-105. doi: 10.1038/bjc.2013.576. Epub 2013 Sep 24.

35.

Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.

Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, Mendez E, Futran N, Wang DX, Chai X, Wallace SG, Austin M, Schmidt R, Hayes DN.

J Clin Oncol. 2013 Apr 10;31(11):1415-21. doi: 10.1200/JCO.2012.46.3299. Epub 2013 Mar 4.

PMID:
23460709
36.

Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study.

Pidala J, Chai X, Kurland BF, Inamoto Y, Flowers ME, Palmer J, Khera N, Jagasia M, Cutler C, Arora M, Vogelsang G, Lee SJ.

Biol Blood Marrow Transplant. 2013 May;19(5):784-91. doi: 10.1016/j.bbmt.2013.02.001. Epub 2013 Feb 6. Erratum in: Biol Blood Marrow Transplant. 2014 Feb;20(2):290.

37.

Accommodation of missing data in supportive and palliative care clinical trials.

Kurland BF, Johnson LL, Diehr PH.

Curr Opin Support Palliat Care. 2012 Dec;6(4):465-70. doi: 10.1097/SPC.0b013e328358441d. Review.

PMID:
23042422
38.

Promise and pitfalls of quantitative imaging in oncology clinical trials.

Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS.

Magn Reson Imaging. 2012 Nov;30(9):1301-12. doi: 10.1016/j.mri.2012.06.009. Epub 2012 Aug 13. Review.

39.

Quantitative assessment of dynamic PET imaging data in cancer imaging.

Muzi M, O'Sullivan F, Mankoff DA, Doot RK, Pierce LA, Kurland BF, Linden HM, Kinahan PE.

Magn Reson Imaging. 2012 Nov;30(9):1203-15. doi: 10.1016/j.mri.2012.05.008. Epub 2012 Jul 21. Review.

40.

Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.

Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, Arai S, Arora M, Jagasia M, Cutler C, Weisdorf D, Martin PJ, Pavletic SZ, Vogelsang G, Lee SJ, Flowers ME.

Blood. 2012 Sep 27;120(13):2545-52; quiz 2774. Epub 2012 Jul 6.

41.

Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.

Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM.

EJNMMI Res. 2012 Jun 25;2(1):34. doi: 10.1186/2191-219X-2-34.

42.

Validation of measurement scales in ocular graft-versus-host disease.

Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, Carpenter PA, Heffernan MJ, Jacobsohn D, Jagasia MH, Pidala J, Khera N, Vogelsang GB, Weisdorf D, Martin PJ, Pavletic SZ, Lee SJ; Chronic GVHD Consortium.

Ophthalmology. 2012 Mar;119(3):487-93. doi: 10.1016/j.ophtha.2011.08.040. Epub 2011 Dec 6.

43.

Design considerations for using PET as a response measure in single site and multicenter clinical trials.

Doot RK, Kurland BF, Kinahan PE, Mankoff DA.

Acad Radiol. 2012 Feb;19(2):184-90. doi: 10.1016/j.acra.2011.10.008. Epub 2011 Nov 21.

44.

Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.

Peterson LM, Kurland BF, Link JM, Schubert EK, Stekhova S, Linden HM, Mankoff DA.

Nucl Med Biol. 2011 Oct;38(7):969-78. doi: 10.1016/j.nucmedbio.2011.03.002. Epub 2011 May 5.

45.

Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.

Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA.

J Nucl Med. 2011 Oct;52(10):1541-9. doi: 10.2967/jnumed.111.091439. Epub 2011 Sep 8.

46.

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA.

Clin Cancer Res. 2011 Jul 15;17(14):4799-805. doi: 10.1158/1078-0432.CCR-10-3321. Epub 2011 Jul 12.

47.

Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium.

Pidala J, Kurland BF, Chai X, Vogelsang G, Weisdorf DJ, Pavletic S, Cutler C, Majhail N, Lee SJ.

Haematologica. 2011 Oct;96(10):1528-35. doi: 10.3324/haematol.2011.046367. Epub 2011 Jun 17.

48.

Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years.

Syrjala KL, Artherholt SB, Kurland BF, Langer SL, Roth-Roemer S, Elrod JB, Dikmen S.

J Clin Oncol. 2011 Jun 10;29(17):2397-404. doi: 10.1200/JCO.2010.33.9119. Epub 2011 May 2.

49.

PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.

Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA.

Clin Cancer Res. 2011 Apr 15;17(8):2400-9. doi: 10.1158/1078-0432.CCR-10-2649. Epub 2011 Mar 1.

50.

Probability of malignancy for lesions detected on breast MRI: a predictive model incorporating BI-RADS imaging features and patient characteristics.

Demartini WB, Kurland BF, Gutierrez RL, Blackmore CC, Peacock S, Lehman CD.

Eur Radiol. 2011 Aug;21(8):1609-17. doi: 10.1007/s00330-011-2094-6. Epub 2011 Feb 27.

PMID:
21359910

Supplemental Content

Loading ...
Support Center